Arsenal Bio: Cutting Staff by Half, Not Cells
Arsenal Bio, one of the rare cell therapy companies still swimming in a sea of failed raises, just laid off nearly half its staff. In a sector where funding looks like a unicorn spotted only in biotech myths, Arsenal Bio managed to raise some capital before executing a harsh 50% staff cull. It’s like hosting a party because you found chips, then eating all the guests. This bittersweet survival dance highlights the brutal biotech winter, reminding us that while cells might fight disease, companies clearly don’t fight layoffs. Half the team out, capital precious: Arsenal Bio’s 2024 cell saga, minus the happy ending.
Share the Story
When your company is 'one of the few able to raise funds' but still chops half your team, your business model is basically survival-of-the-fittest meets corporate Hunger Games.
Arsenal Bio raised cash but still slashed half the staff. Nothing says 'biotech innovation' like 'hope you like unemployment.'
Cell therapy startup Arsenal Bio proves even in science, you’re half as likely to keep your job as to get stem cells.
Source: Statnews | Published: 9/17/2025 | Author: Jason Mast
More Articles in Business
Salesforce AI Flops, Google Car-Dwellers & Senior Homebuyers Take Over
KPMG’s 450K Sq.Ft NYC HQ: Employee Feedback or Round Table Cult?
Rivian CEO’s $4.6B Stock Option: Billionaire or Billion Procrastinator?
DoorDash Execs Fail at Delivery, Beta-Test Their Own Chaos
Parenting & Two Jobs: Health Writer Floors Architectural Chaos!
